Demands for access to new therapies: are there alternatives to accelerated access?BMJ 2017; 359 doi: https://doi.org/10.1136/bmj.j4494 (Published 02 October 2017) Cite this as: BMJ 2017;359:j4494
All rapid responses
Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles or when it is brought to our attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not including references and author details. We will no longer post responses that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
Encouraging the collection of data even after a drug is on the market is wise, and the key to doing so is flexibility. Examples in practice are the two Managed Access Agreements in place to allow patients in England with life-threatening rare diseases to access drugs while more evidence is gathered on their efficacy. This includes one for the first muscular dystrophy treatment, Translarna.
We need to more flexibility like this, as well as innovative risk-sharing agreements and variable pricing structures – an opposite direction of travel to the recent introduction of drug pricing and QALY caps. The charity Muscular Dystrophy UK has launched its Fast Track campaign to encourage this approach and to address some of the many delays and barriers that stop patients with rare genetic conditions, including muscular dystrophy, from accessing high-cost personalised treatments. A more nuanced approval process and savvier commercial negotiations with drug companies will help to ensure treatment gets to patients at an affordable price to the NHS.
Competing interests: No competing interests